Looking for Kinetico Water Systems? Click Here!

Commercial Strategy Biopharmaceutical Practice

Our Commercial Strategy services help biopharmaceutical companies maximize the commercial value of their products across all phases of the product lifecycle.

Service lines include:

Business Model Design

Commercialize vs. Partner

Regional Strategies

Cost / Benefit and ROI Analysis

Market Access

Payer Interviews

Health Economics (HECON) / Real World Evidence (RWE) Analysis

Pricing / Discount Strategies



Scenario-based Financial Models

Key Assumption Development

Peak Year and Beyond Forecasts

Click the Tabs Below for Case Studies, White Papers and Articles, and Blog


Case Studies
  • Commercial Strategy

    Situation: A mid-size pharmaceutical company unexpectedly obtained a marketed CNS drug and needed to understand the financial impact of various


    Read this Case Study

  • Portfolio Optimization

    Situation: A fully integrated pharmaceutical company developing a class of immuno-oncology therapies was in need of a deeper understanding of


    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 


    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the


    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and


    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and


    Read this Case Study

  • What Can China Teach Us About CAR-T?

    What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China


    Read this Article

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index,


    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

    Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet


    Read this Article

  • Bridges and Barriers to Advancing CAR T Therapy

    One result of the Oncology explosion over the past 10 years has been the advent of CAR T therapy. In


    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as


    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?


    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent


    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion


    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies


    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its


    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute